Haemonetics (NYSE:HAE) Downgraded by Wall Street Zen to Buy

Key Points

• Wall Street Zen downgraded Haemonetics from “Strong Buy” to “Buy.” Despite the downgrade, analysts’ overall consensus remains “Moderate Buy,” with an average price target of $126.38.
• Haemonetics beat quarterly earnings and revenue estimates. It reported $1.35 in earnings per share versus $1.29 expected, and revenue of $357.76 million, up 9.4% year over year.
• Several analysts raised their price targets, including BTIG to $142 and Barrington Research to $145, while the shares were reported down 3.4%.

Haemonetics (NYSE:HAE - Get Free Report) was downgraded by analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a research report issued on Saturday, Wall Street Zen reports.

A number of other research analysts have also recently commented on HAE. BTIG Research upped their price objective on Haemonetics from $130.00 to $142.00 and gave the company a "buy" rating in a report on Thursday. Raymond James Financial lifted their price objective on Haemonetics from $105.00 to $125.00 and gave the company an "outperform" rating in a research report on Thursday, September 3rd. Robert W. Baird upped their target price on shares of Haemonetics from $96.00 to $119.00 and gave the stock an "outperform" rating in a research report on Friday, August 21st. Weiss Ratings raised shares of Haemonetics from a "hold (c-)" rating to a "hold (c)" rating in a research note on Tuesday, August 11th. Finally, Barrington Research raised their target price on shares of Haemonetics from $140.00 to $145.00 and gave the company an "outperform" rating in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $126.38.

Haemonetics Trading Down 3.4%

HAE stock opened at $119.87 on Friday. The company has a market cap of $5.45 billion, a P/E ratio of 23.98, a PEG ratio of 2.40 and a beta of 0.63. The company has a quick ratio of 1.91, a current ratio of 3.08 and a debt-to-equity ratio of 1.40. The business has a fifty day moving average of $111.48 and a 200-day moving average of $80.05. Haemonetics has a twelve month low of $51.00 and a twelve month high of $132.00.

Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The medical instruments supplier reported $1.35 earnings per share for the quarter, topping the consensus estimate of $1.29 by $0.06. Haemonetics had a net margin of 7.12% and a return on equity of 27.55%. The company had revenue of $357.76 million for the quarter, compared to analysts' expectations of $345.15 million. During the same quarter in the previous year, the firm posted $1.27 earnings per share. Haemonetics's revenue for the quarter was up 9.4% on a year-over-year basis. As a group, equities research analysts expect that Haemonetics will post 5.29 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Nierenberg Investment Management Company LLC purchased a new position in shares of Haemonetics during the second quarter valued at approximately $1,971,000. Rice Hall James & Associates LLC bought a new stake in Haemonetics during the 2nd quarter valued at $3,828,000. Renaissance Technologies LLC purchased a new position in Haemonetics during the 1st quarter worth $2,435,000. Quantinno Capital Management LP increased its holdings in Haemonetics by 438.0% in the first quarter. Quantinno Capital Management LP now owns 30,708 shares of the medical instruments supplier's stock valued at $1,731,000 after buying an additional 25,000 shares in the last quarter. Finally, Aurora Investment Counsel acquired a new stake in shares of Haemonetics in the second quarter valued at about $1,913,000. Institutional investors own 99.67% of the company's stock.

Key Haemonetics News

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Quarterly results beat expectations: Haemonetics earned $1.35 per share versus estimates of $1.29 and generated $357.8 million in revenue, above the $345.2 million consensus and up 9.4% year over year. Earnings and outlook report
• Positive Sentiment: Raised fiscal 2027 outlook: The company increased its full-year revenue and organic-growth outlook, forecasting organic growth of 6%–9%. Fiscal 2027 outlook
• Positive Sentiment: Analyst price targets rose: Citigroup raised its target to $149 and maintained a Buy rating; Barrington Research lifted its target to $145 with an Outperform rating; and BTIG raised its target to $142 with a Buy rating. Citigroup recommendations
• Neutral Sentiment: Growth comes with execution considerations: Haemonetics plans to scale the CSL Persona PLUS rollout through calendar 2027, and earnings-call coverage noted growth and margin tradeoffs. This may temper enthusiasm if rollout costs or margins disappoint. Earnings call highlights

Haemonetics Company Profile

Haemonetics Corporation NYSE: HAE is a healthcare technology company that develops and supplies products and services for blood and plasma collection, processing, and management. Its solutions are used by blood and plasma collection organizations, hospitals, and other healthcare providers to support the efficient handling of blood components and improve patient care.

The company's offerings include automated plasma and blood-component collection systems, disposable collection sets, blood-processing equipment, and software designed to manage collection and transfusion-related operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.